Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your Favored Kind of Scarf - 2Instructions to Pick the Right Dental Expert for Teeth Substitution
- 3Washington resident is infected with a different type of bird flu
- 4Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 5Which Breakfast Enraptures Your Taste Buds? Vote
- The Most Important Crossroads in Olympic History
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Which Switch Game Do You Suggest? Share Your Decision
- How one man's concern saved his brothers from heart disease
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- A Manual for SUVs with Less Noteworthy Gas Mileage
- Study shows no clear link between low-fat dairy and dementia risk
- Bird flu poses risk of pandemic worse than COVID, France's Institut Pasteur says
